HRP20181583T1 - Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata - Google Patents

Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata

Info

Publication number
HRP20181583T1
HRP20181583T1 HRP20181583TT HRP20181583T HRP20181583T1 HR P20181583 T1 HRP20181583 T1 HR P20181583T1 HR P20181583T T HRP20181583T T HR P20181583TT HR P20181583 T HRP20181583 T HR P20181583T HR P20181583 T1 HRP20181583 T1 HR P20181583T1
Authority
HR
Croatia
Prior art keywords
carbamoyl
ethenylcyclopropylcarboxylic
iloxy
cyclopropylsulfonyl
dimethylpropyl
Prior art date
Application number
HRP20181583TT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Kevin Perrone
Original Assignee
Bristol-Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181583(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Holdings Ireland filed Critical Bristol-Myers Squibb Holdings Ireland
Publication of HRP20181583T1 publication Critical patent/HRP20181583T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20181583TT 2012-05-07 2013-04-30 Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata HRP20181583T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07
EP13722217.0A EP2846780B1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
PCT/US2013/038770 WO2013169520A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (1)

Publication Number Publication Date
HRP20181583T1 true HRP20181583T1 (hr) 2018-11-30

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181583TT HRP20181583T1 (hr) 2012-05-07 2013-04-30 Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata

Country Status (33)

Country Link
US (1) US20130302414A1 (enExample)
EP (1) EP2846780B1 (enExample)
JP (1) JP6276756B2 (enExample)
KR (1) KR20150004921A (enExample)
CN (1) CN104363899A (enExample)
AR (1) AR090954A1 (enExample)
AU (1) AU2013260005B2 (enExample)
BR (1) BR112014027676A2 (enExample)
CA (1) CA2872765A1 (enExample)
CL (1) CL2014003012A1 (enExample)
CO (1) CO7141457A2 (enExample)
CY (1) CY1120756T1 (enExample)
DK (1) DK2846780T3 (enExample)
EA (1) EA028749B1 (enExample)
ES (1) ES2688817T3 (enExample)
HR (1) HRP20181583T1 (enExample)
IL (1) IL235466B (enExample)
LT (1) LT2846780T (enExample)
MX (1) MX358545B (enExample)
MY (1) MY171378A (enExample)
NZ (1) NZ630248A (enExample)
PE (1) PE20142439A1 (enExample)
PH (1) PH12014502405A1 (enExample)
PL (1) PL2846780T3 (enExample)
PT (1) PT2846780T (enExample)
RS (1) RS57881B1 (enExample)
SG (1) SG11201406964QA (enExample)
SI (1) SI2846780T1 (enExample)
SM (1) SMT201800506T1 (enExample)
TW (1) TWI577392B (enExample)
UY (1) UY34785A (enExample)
WO (1) WO2013169520A1 (enExample)
ZA (1) ZA201408967B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169577A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
PL3765024T3 (pl) 2018-03-14 2024-08-05 KaNDy Therapeutics Limited <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div>
AU2019404026B2 (en) * 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
EA006759B1 (ru) * 2000-10-31 2006-04-28 Бёрингер Ингельхайм Фармасьютиклз, Инк. Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由5,6-二氫-1h-吡啶-2-酮與一或多種其他抗病毒化合物的組合物抑制c型肝炎病毒的方法
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
EP2846780A1 (en) 2015-03-18
JP6276756B2 (ja) 2018-02-07
MX2014013220A (es) 2015-05-11
PL2846780T3 (pl) 2018-11-30
US20130302414A1 (en) 2013-11-14
EA201492039A1 (ru) 2015-02-27
ES2688817T3 (es) 2018-11-07
SG11201406964QA (en) 2014-11-27
KR20150004921A (ko) 2015-01-13
AU2013260005B2 (en) 2017-07-13
PH12014502405A1 (en) 2015-01-12
CO7141457A2 (es) 2014-12-12
IL235466B (en) 2019-03-31
EA028749B1 (ru) 2017-12-29
AU2013260005A1 (en) 2015-01-15
BR112014027676A2 (pt) 2017-06-27
CY1120756T1 (el) 2019-12-11
MX358545B (es) 2018-08-24
MY171378A (en) 2019-10-10
SI2846780T1 (sl) 2018-09-28
PT2846780T (pt) 2018-10-26
PE20142439A1 (es) 2015-01-28
CN104363899A (zh) 2015-02-18
LT2846780T (lt) 2018-11-12
RS57881B1 (sr) 2019-01-31
WO2013169520A1 (en) 2013-11-14
CA2872765A1 (en) 2013-11-14
HK1204552A1 (en) 2015-11-27
TWI577392B (zh) 2017-04-11
SMT201800506T1 (it) 2018-11-09
ZA201408967B (en) 2016-10-26
EP2846780B1 (en) 2018-07-18
CL2014003012A1 (es) 2015-07-10
UY34785A (es) 2013-11-29
AR090954A1 (es) 2014-12-17
DK2846780T3 (en) 2018-09-17
NZ630248A (en) 2016-11-25
TW201350145A (zh) 2013-12-16
JP2015516418A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
IL235466B (en) Dissolved capsule formulation of 1,1–dimethylethyl[(71)–4–(r4,s2)]}–1–(s–chloro–4 methoxyisoquinoline–1–yloxy)–2–{(11–(s2,r– [(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidine-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
BR112012030906A2 (pt) derivados de carbamato de hexaflúor isopropila, sua preparação e sua aplicação terapêutica
WO2014052360A3 (en) Glycoprotein preparations
CA2796215C (en) Compositions and methods for brain delivery of analgesic peptides
EP3024472A4 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
IL232333A (en) N- (pyrid-4-ram) amides and n- (pyrimidin-4-ram) amides and their pharmacological and cosmetic uses
HUS2300030I1 (hu) N-(2-metoxibenzoil)-4-[(metilaminokarbonil)amino]benzolszulfonamid polimorf formája
WO2011130615A3 (en) Preparation of lacosamide
HUE045111T2 (hu) N-(2-metoxibenzil)-4-[(metilaminokarbonil)amino]benzolszulfonamid inszekticidekkel vagy fungicidekkel képzett kombinációjának alkalmazása növénytermesztés hatásfokának növelésére
PT2849745T (pt) Composição farmacêutica compreendendo (1r,4r)-6&#39;-fluoro-n,n-dimetil-4-fenil-4&#39;,9&#39;-di-hidro-3&#39;h-espiro[ciclo-hexano-1,1&#39;-pirano[3,4,b]indol]-4-amina e ibuprofeno
BR112013006128A2 (pt) preparações pesticidas contendo ésteres de ácido 2-pirrolidono-4-carboxílico n-substituídos
BR112014028574A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um gabapentinoide
BR112014028562A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e antidepressivos
BR112014028569A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um oxicam
BR112014028566A2 (pt) composição farmacêutica compreendendo ( 1r , 4r ) - 6 - fluoro n , n - dimetill - 4 - fenil - 4 , 9 - di - hidro - 3h espiro ( ciclohexano 1-1 - pirano ( 3,4,b) indo ) - 4 - amina e um nsar.
TH1401006625A (th) สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต
EP2890368A4 (en) RECIPE FOR A DOUBLE-LAYER COMPOSITE TABLET WITH ATORVASTATIN, IRBESARTAN AND MAGNESIUM CARBONATE
ZA201403735B (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
MX2013015272A (es) Cristales micronizados.
PL2678006T3 (pl) Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu
BR112014028564A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um componente de ácido salicílico
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo
HK1218512A1 (zh) 雜環化合物和其用途
ZA201602238B (en) Preservative free pharmaceutical composition for ophthalmic administration containing bimatoprost and timolol
HK1224596A1 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof